Source: Virtual Congress 2020 – Inhaler devices in COPD: technical advances, adherence studies and more
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Farkas (Budapest, Hungary), A. Horváth (Budapest, Hungary), G. Tomisa (Budapest, Hungary), G. Gálffy (Törökbálint, Hungary), J. Varga (Budapest, Hungary). Numerical simulation of the effect of inhalation parameters and disease severity on the deposition of dry powder aerosol drugs in COPD patients. 629

Member's Comments

No comment yet.

Related content which might interest you: Computerized measurements of inhalation ability with a dry powder inhaler in patients with severe COPD Source: Virtual Congress 2020 – Inhaler devices in COPD: technical advances, adherence studies and more Year: 2020 The investigation of inhalation continuous duration for dry powder inhalers in asthmatic patients Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012 Systemic availability (lung deposition) of drug from two different dry powder inhalers in children with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 429s Year: 2002 Improving inhalation parameters through dry powder inhalers (DPIs) after an acute asthma exacerbation Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012 Dose delivery characteristics of two dry powder inhalers in COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 291s Year: 2004 Inspiratory profiles and consistency of behaviour regarding dose delivery characteristics of two dry powder inhalers in COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 13s Year: 2004 Analysis of peak inspiratory flow and use of dry powder inhalers in patients with chronic obstructive pulmonary disease Source: International Congress 2019 – COPD treatment: clinical trials, cohorts and inhaler device studies Year: 2019 Prevalence of bronchoconstriction in patients with bronchiectasis assessed prior to treatment with a dry powder preparation of mannitol Source: Annual Congress 2007 - Current issues in airway physiology, pharmacology and monitoring Year: 2007 Carbon footprint of severe asthma exacerbation management relative to Breezhaler dry powder inhaler Source: Virtual Congress 2021 – Environment and respiratory health Year: 2021 Safety and pharmacokinetics of two dose strengths of ciprofloxacin dry powder for inhalation (DPI) in patients with moderate to severe COPD Source: Annual Congress 2012 - Hot topics in respiratory infections Year: 2012 Investigation of breathing parameters of COPD patients inhaling through three different DPI devices Source: International Congress 2018 – Pharmacological management of COPD Year: 2018 Efficacy of inhalation from different powder inhalators in COPD patiens with chronic respiratory failure Source: Eur Respir J 2006; 28: Suppl. 50, 210s Year: 2006 Impact of PAHs exposure on exacerbation frequency in asthma using a new grid-scale simulation of PM2.5-PAHs distribution Source: Virtual Congress 2020 – Air pollution and comorbidities Year: 2020 The effect of oral corticosteroid on spirometeric parameters in COPD patients induced by mustard gas Source: Eur Respir J 2006; 28: Suppl. 50, 216s Year: 2006 In vitro fine particle dose of drug formulation used in asthma & COPD Source: Virtual Congress 2020 – Asthma inhalers: devices and adherence studies Year: 2020 Effect of dust aerosol in patients with asthma Source: Annual Congress 2011 - Diagnosis and treatment of inflammatory respiratory diseases Year: 2011 Extent of inhaled drug deposition at variable inhaler inclination angles and airway geometries: An in-vivo study from a novel computational fluid dynamics model Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Consider the turbulent energy not inhalation flow when patients use dry powder inhalers (DPIs) Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012 Increased asthma medication use in association with ambient fine and ultrafine particles Source: Eur Respir J 2002; 20: 691-702 Year: 2002 The small airway inflammation of asthmatic patients who have used dry powder type inhaled steroid for moderate-long term evaluated by induced sputum and the efficacy of HFA-BDP (QVAR) inhalation Source: Eur Respir J 2005; 26: Suppl. 49, 503s Year: 2005